Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2016 - 2025)

Celldex Therapeutics has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $816000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $816000.0 for Q4 2025, changed 0.37% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 6.39% YoY), and the annual figure for FY2025 was $3.4 million, up 6.39%.
  • Depreciation & Amortization (CF) for Q4 2025 was $816000.0 at Celldex Therapeutics, down from $824000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CLDX hit a ceiling of $873000.0 in Q2 2025 and a floor of $671000.0 in Q3 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $775000.0 (2021), compared with a mean of $776450.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): crashed 33.48% in 2021 and later rose 14.31% in 2023.
  • Celldex Therapeutics' Depreciation & Amortization (CF) stood at $777000.0 in 2021, then dropped by 13.38% to $673000.0 in 2022, then grew by 12.78% to $759000.0 in 2023, then increased by 7.91% to $819000.0 in 2024, then decreased by 0.37% to $816000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $816000.0 (Q4 2025), $824000.0 (Q3 2025), and $873000.0 (Q2 2025) per Business Quant data.